Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Body composition and efficacy of Camrelizumab in solid tumors
ChiCTR2500097894Phase 4Not yet recruiting
- Sponsor
- First People's Hospital of Ziyang
- Start
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC) and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First People's Hospital of Ziyang. Primary endpoint: Objective response rate. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500097894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097894.